2013
DOI: 10.1590/0004-282x20130121
|View full text |Cite
|
Sign up to set email alerts
|

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Abstract: Objective: Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method: Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). Results: In a group of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
7
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 8 publications
(9 citation statements)
references
References 10 publications
2
7
0
Order By: Relevance
“…Subclinical JCV reactivation may also occur in blood of natalizumab-treated MS patients, as we and others have previously reported 68, 13, 28 . We found JCV in blood of 9 of 32 (28.1%) natalizumab-treated patients, a result comparable to viremia of 35% in a different cohort, recently reported by Major et al 29 .…”
Section: Discussionsupporting
confidence: 64%
“…Subclinical JCV reactivation may also occur in blood of natalizumab-treated MS patients, as we and others have previously reported 68, 13, 28 . We found JCV in blood of 9 of 32 (28.1%) natalizumab-treated patients, a result comparable to viremia of 35% in a different cohort, recently reported by Major et al 29 .…”
Section: Discussionsupporting
confidence: 64%
“…In fact, although secondgeneration STRATIFY JCV Ⓡ showed an increased sensitivity, some patients present a negativity to anti-JCPyV antibodies and a detectable JCPyV DNA in urine or blood. Our data confirm that anti-JCPyV antibodies assay, alone, is not sufficient for JCPyV diagnosis and should be associated with JCPyV-DNA detection in different body compartments, in order to accurately identify JCPyV infected patients (Fragoso et al, 2013;Major et al, 2013;Delbue et al, 2015). Consequently, different approaches to detect JCPyV infection are required for a more accurate Table 3 Contextual analysis of the anti-JCPyV antibodies versus JCPyV-DNA detection.…”
Section: Discussionmentioning
confidence: 52%
“…The risk of seropositivity rises with increasing age and male gender . But several reports show that the annualized seroconversion rate in natalizumab‐treated patients with MS seems to be higher than expected, possibly due to a higher sensitivity caused by natalizumab usage …”
Section: Introductionmentioning
confidence: 96%
“…Patients with anti‐JCV antibodies in serum or plasma are at risk for developing PML. Although 33‐91% of the general population is positive for this virus, epidemiologic data in patients with MS show that about half of the patients seem to be positive for JCV antibodies …”
Section: Introductionmentioning
confidence: 99%